Start with the exact drug and biomarker question, not a general request
Targeted cancer treatment acts on particular molecular features, and biomarker findings can help clinicians assess potential treatment options. That sentence is the whole clinical frame for this handover. It does not tell you which drug fits which mutation, and it does not mean every biomarker result leads to an available medicine. What it does mean is that a vague request such as "please review my cancer records for targeted therapy" gives the receiving team almost nothing to work with.
A workable request names the drug or drug class already discussed, the biomarker result that prompted it, and the decision your home team is trying to make. For example: the home oncologist has proposed a specific targeted agent based on a named biomarker, the patient wants to know whether a centre in China can assess that same context, and the family needs to understand how treatment and monitoring would continue if the patient travelled. That is a question a specialist can answer. "Can you treat my cancer?" is not.
Write the question down before you send anything. One paragraph is enough. It should state the diagnosis, the stage as recorded by your home team, the biomarker result with the test report attached, the drugs already given with dates, the current drug and response as documented, and the single decision you need help with. If you cannot state the decision in one sentence, the handover is not ready.
What your home team should actually send
A frequent problem in cross-border cancer communication is not missing records. It is records that arrive without the interpretation that makes them usable. A pathology report in one language, a genomic report in another, and a discharge summary that lists drugs by brand name only will slow any review, and may lead to a request for repeat testing that could have been avoided.
Ask your home team for a short cover letter, on letterhead, signed by the treating oncologist. It should confirm the diagnosis and stage, list the biomarker tests performed with the laboratory name and the result, list prior and current systemic treatments with start and stop dates and the reason each was stopped, describe the current response and any toxicity that limited treatment, and state the specific question the home team wants answered. This letter is more valuable than another hundred pages of scans.
Then attach the primary documents the letter refers to: the pathology report, the molecular or genomic test report including the assay used and the variants reported, the most recent imaging reports, and the current medication list with doses. If the home team has already consulted another centre, include that opinion too. A receiving clinician needs to see the reasoning, not only the conclusion.
If some documents do not exist, say so. A missing biomarker report is a different situation from a biomarker report that was done and showed nothing actionable. The receiving team needs to know which one applies before it can tell you what it can and cannot assess.
What to ask the China centre before you send anything
Before you transfer a full file, ask three questions. First: can this centre assess a case with this diagnosis and this biomarker context, and if so, which specialty or multidisciplinary team would review it? Second: what does the centre need in order to give a records-based opinion, and in what language? Third: if the patient were to travel, how would ongoing treatment and monitoring be arranged, and what would the home team need to provide for continuity?
These questions matter because a records-based opinion is not the same as hospital acceptance, and neither is the same as confirmed access to a particular medicine. A centre may be able to review the file and discuss options without being able to confirm that a specific drug is available, funded, or appropriate for this patient. Ask explicitly which of those three things the reply covers.
You should also ask how the reply will be delivered and to whom. A written opinion addressed to the home oncologist is more useful than a verbal summary to the family, because it can be filed, compared with the home plan, and acted on. If the centre prefers to speak with the home team directly, ask how that conversation would be arranged and whether an interpreter is needed.
Do not treat a preliminary reply as a decision. An initial response that the case is suitable for review means only that. It does not establish eligibility for a trial, access to a named medicine, or a treatment plan.
The handover has two directions, and both need an owner
Families tend to focus on getting records out. The harder half is getting a usable reply back to the home oncologist, and making sure someone is responsible for acting on it. Before you start, agree with your home team who will receive the reply, who will read it, and when. If the home oncologist is willing to review a written opinion from China, say so in the cover letter. If not, you need to know that before you spend time and money on a review.
On the China side, ask who owns the case file and who will answer follow-up questions. A single named contact, whether a coordinator or a clinical office, prevents the situation where three people each hold part of the file and no one can confirm what was sent. Ask for a written list of documents received, so gaps are visible early rather than after a review has started.
If the two teams disagree, that disagreement is itself useful information. Ask each side to state the basis for its view: which guideline, which trial, which prior response. A disagreement about a specific drug in a specific biomarker context is a clinical question for the treating clinicians. Your job is to make sure both sides are looking at the same records and answering the same question.
Language, consent and what not to send
Ask the receiving centre what language it needs for reports and what it will provide in return. If certified translation is required, find out before sending, because a partial translation can be worse than none. Keep a copy of everything you send, in the language you sent it, so you can compare it with any reply.
Consent matters for a records-based review. The patient, or the person legally authorised to act for them, should confirm in writing that records may be shared with the named centre and that a reply may be sent to the named home clinician. Ask the centre what it requires; do not assume a form you found elsewhere will be accepted.
Do not send passport numbers, payment card details, or a complete medical archive in a first message. A short summary with the diagnosis, the biomarker context, the current treatment and the specific question is enough to start. The full file follows once both sides have agreed what is needed and who will handle it.
If the patient is currently unwell, or treatment is due, local care comes first. An overseas enquiry should not delay a decision that your home team needs to make now.
A practical sequence, and the next step
Write the one-sentence question. Ask your home oncologist for the signed cover letter and the primary reports it refers to. Ask the China centre, in writing, whether it can assess this diagnosis and biomarker context, what it needs, and how ongoing treatment and monitoring would continue if the patient travelled. Send the summary, not the archive. Get a written list of what was received. Get the reply in writing, addressed to the home team. Confirm who acts on it.
ChinaSpecialistCare can help with the practical side of this exchange: clarifying what a centre needs, arranging interpretation, and requesting a specialist appointment once the records and the question are clear. The clinical decisions, suitability and any treatment plan belong to the treating clinicians on both sides.
You can start with a free initial enquiry. Send a brief summary and your main question; the team will tell you what is missing and what the relevant next step is. You do not need to buy a proxy consultation to make that first contact.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.